hydrazine has been researched along with Endometrial Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bergamini, A; Cibula, D; Fariñas-Madrid, L; Guerra, EM; Hamilton, EP; Henry, S; Høgdall, E; Kauffman, MG; Klat, J; Levy, T; Makker, V; Martínez-Garcia, J; Michel, D; Miller, DS; Mirza, MR; Monk, BJ; Pérez-Fidalgo, JA; Pothuri, B; Raspagliesi, F; Richardson, DL; Romero, I; Scambia, G; Schochter, F; Sehouli, J; Shacham, S; Slomovitz, B; Valabrega, G; Van Gorp, T; Vergote, I; Welch, S; Wimberger, P | 1 |
| Gouda, MA; Thein, KZ | 1 |
| Kaake, M; Low, PS; Roy, J; Srinivasarao, M | 1 |
1 trial(s) available for hydrazine and Endometrial Neoplasms
| Article | Year |
|---|---|
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Endometrial Neoplasms; Female; Humans; Hydrazines; Prospective Studies; Triazoles | 2023 |
2 other study(ies) available for hydrazine and Endometrial Neoplasms
| Article | Year |
|---|---|
Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?
Topics: Endometrial Neoplasms; Female; Humans; Hydrazines; Neoplasm Recurrence, Local; Triazoles; Tumor Suppressor Protein p53 | 2023 |
Targeted Tubulysin B Hydrazide Conjugate for the Treatment of Luteinizing Hormone-Releasing Hormone Receptor-Positive Cancers.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Delivery Systems; Endometrial Neoplasms; Female; Heterografts; Humans; Hydrazines; Male; Mice; Oligopeptides; Ovarian Neoplasms; Pipecolic Acids; Prostatic Neoplasms; Receptors, LHRH; Thymine | 2018 |